Gpi Spa · MIL:GPI
Gpi Spa — Investor Presentation (May 2022)
30 slides from Gpi Spa's investor presentation, May 2022
Slide 1: Investor Presentation FY21
INVESTOR PRESENTATION FY21 May 2022
Slide 2: Your Global Partner for a Better Future
> 30 years of experience, management History of Your Global Partner Growth team with a track record of internal growth and M&As for a Better Future International footprint solutions used by 2,500 customers in more than 70 countries We develop software, technologies and services to help innovating th
Slide 3: Sustainability and the Health Care Market
Sustainability and the Health Care Market DIGITAL Increasing Health Spending TRANSFORMATION • Demographic factors (population ageing) • Redesign processes • Citizens and patient expectations • New technologies and treatments • Prevention and control of NCDs Chronic diseases befall the world at large
Slide 4: A History of Steady Growth
+ 30.6% + 20.6% 326.9 YoY YoY EXPORT 9.6% 70% 271.0 a Recurring fees History of Steady 16,7% on adj. Revenue Growth ITALY 90.4% 15,2% on tot. Revenue 16.0% 14.8% H Public 49.8 81.3% 40.2 7,217 Employees 2,700 Clients 70 Countries € 100 M M&A deals in the last 5 years 6.2% H Private FY 20 FY 21 FY 20
Slide 5: Strategic Business Areas
Segmentation FY21 TECHNOLOGIES Strategic TECHNOLOGIES 49.2% 82.4% Software 36.0% Business Software 66.3% Pay 3.4% Areas Pay 7.7% Automation 4.3% ICT 5.5% Automation 5.6% ICT 2.8% Care 50.8% Care 17.6% SERVICES SERVICES 50.8% 17.6% Revenue EBITDA Integrate the value of Persons with the value of Techn
Slide 6: Supply Lines
Supply Lines • hospital information system • health social care • blood transfusion & tissue bank Software • health administration • Business Intelligence, data analytics main SBAs • other 86.8% of total revenue • BPO health care administrative svc. (AtC,..) • telemedicine Care • other • automated p
Slide 7: Highlights FY21 M&As - Blood Bank
Highlights FY21 M&As - Blood Bank • Proceeds from exercise of warrants € 22.3 M Haemonetics operation Funding M&As $ 11.3 M Rev. |35% EBITDA 100 clients in the USA (2020) • CERVED confirmes rating at A3.1 A- S&P |A3 Moody’s | A-1 Fitch equivalent Medinfo Group € 3.9 M Rev. | 36% EBITDA • 147 Bids |
Slide 8: Actual Projects
Actual Projects Real answers to Covid- 19: concretely implementing the Group’s vision: the Patient at the Centre Informational Services 24/7 APPs indoor navigation and patient tracking SW for the management of swab tests and vaccine jabs Vaccination programme Artificial Intelligence based, risk stra
Slide 9: Solid Growth FY21
Solid Growth FY21 Revenue € 326.9 M +20.6% | 16.2% organic €M FY21 FY20 thanks to the contribution of the SBAs: • SW € 117.6M +14.6% Revenue & other income 326.9 271.0 • Care €166.2 M +25.4% Adjusted Revenue(1) 298.1 250.9 • Other € 43.1 M +20.1% EBITDA 49.8 40.2 EBITDA: € 49.8 M | 16.7% on adj. Rev
Slide 10: Financial Highlights FY21
Financial Highlights FY21 A3.1 CERVED Rating A- S&P |A3 Moody’s | A-1 Fitch equivalent Non-current assets €M FY21 FY20 The increase in Non-current is linked to the investments, Restated including the acquisition of Medinfo Non-current assets 166.8 158.4 Net Working Capital The increase is due to the
Slide 11: Net Debt
Net Debt Financial Net Debt Investments ass./liab. (M&A) 16.1 According to New ESMA Net Dividend & 34.5 Net Debt Guideline No. 39, issued Net Debt Capex (tang.) interests warrants 31/12/2021 on March 4th 2021 31/12/2020 Capex 5.5 14.3 155.4 restated EBITDA 6.4 49.8 (intang.) 144.5 14.3 NWC & other T
Slide 12: Software FY21
Software FY21 2° player ITA +15.5% 116.8 1-3 years Average contract length 49% 101.1 50% tenders win-ratio Recurring fees 89% Retention 28.3% Clinical 27.0% 14.5% Health ERP 32.1% 9.1% Blood MS 33.0 HR/PA 13.2% 27.3 BI & Data Analytics 12.0% 90.8 19.1% Other 22.3* Revenues by Business Unit Adj. Reve
Slide 13: Care FY21
Care FY21 +25.4% 138.2 1° player ITA 4-6 years Average contract length 113.9 91% 45% tenders win-ratio 97% Retention Recurring fees 1.7% 6.5% 6.4% AtC - administr. svc. & other Virtual Care 8.8 90.8 7.4 98.3% 22.3* Revenues by Business Unit Adj. Revenue €M % on total SBA’s revenue Net of Temporary C
Slide 14: Other SBAs
Other SBAs AUTOMATION Automated warehouse sales, maintenance and service fees +20% • Retail Pharmacies • Hospital Pharmacies 43.1 • Wholesaler and other industries 35.8 PAY 14.0 Automation ePayment services 11.9 POS rental and related software 8.0 • Large-scale Retail; 11.3 Pay • Local PA 9.0 5.4 •
Slide 15: Competitive environment and strategic guidelines
Competitive environment and strategic guidelines
Slide 16: Market Assessment Software and IT Services
Market Assessment Software and IT Services Source: Gartner Hospital + Physician survey (2021 Q4) value of the Global market for health care software + IT services in 2021 $79.7 B +14.8% 2021 on 2020 CAGR 21 – 24: 12.2% 47.9% North America CAGR 21 – 24: 12.0% 30.8% Western Europe CAGR 21 – 24: 12.1%
Slide 17: Competitive Ranking
Competitive Ranking Top Players in Italy Software BPO AtC Company Brief description Focus on Ranking > 29 M citizens reached HC ICT solutions and related Company Brief description Ranking services for public and private healthcare providers. 1st ICT solutions, administrative and ICT solutions, adm
Slide 18: The 5 Pillars
The 5 Pillars Strategic intentions 2020-2024 01 02 03 04 05 EVER PRIVATE MARKET INTEGRATED FROM HEALTH LEADERSHIP SOLUTIONS PROVIDER MORE CARE in ITALY TO PARTNER GLOBAL Strong increase Doubling up of Major regional and Greater integration Multi-business over the BP the Private HC national tenders o
Slide 19: M&A Guidelines
M&A Guidelines (cTe)|
Slide 20: Historic M&A process
established in October e Historic M&A process ACQUIRED Spid (16%) Selfin health) INCREASED HOLDING IN Sysline (70%) ESTABLISHED CRG ‘MADO ACQUIRED & CONSOLIDATED Logicast (100%) area (100%) Argentea (100%) ACQUIRED Sysline(65%) ESTABLISHED Selfin.it ACQUIRED GCS (health) ACQUIRED imtac (23%) CONSOLI
Slide 21: M&A Guidelines Become a Major European Player
M&A Guidelines Become a Major European Player • Structured software Product Portfolio companies Evolution software|services| • Product Portfolio Evolution territories Blood Management System Software TARGET 3 Jan 2022 - LOI acquisition of TESI Group LIS | RIS/PACS | Blood Italy, Mexico, Brazil FY20
Slide 22: Investment Attractiveness
Investment Attractiveness SHAREHOLDING STRUCTURE Leadership and Uniqueness GPI IN THE STOCK MARKET ISIN: IT0005221517 Treasury shares FM srl Ticker: GPI:IM 0.56% 57.31% Price 4 May 2022 € 13.04 Growth and Visibility Ordinary Shares 18,260,496 Capitalisation € M 238 Technology and Service ANALYSTS’ C
Slide 23: Gpi vs FTSE small cap and mid cap
1 Year YTD Gpi + 52.9% -23.1% FTSE small cap + 25.8% -8.4% FTSE mid cap + 12.7% -18.7%
Slide 24: A New Architecture of Integrated Solutions
A New Architecture of Integrated Solutions Threshold Values and Alert Structured Interaction with Patients Monitoring Dashboard Proactivity and Care IoT – Sensors – Dedicated Apps Intelligent Cloud Management Dataflow Monitoring Direct Interaction with Patients Technologies for Enabling Disease Pati
Slide 25: BPC - Business Package Capabilities
BPC - Business Package Capabilities POHEMA components <#@ POHEMA/APP <#@ POHEMA/TECH W POHEMA/CARE GAIA Population analysis and stratification TAKE CARE Individual assistance plan management system PHEBO Telemedicine and Telemonitoring Platform DOC-AVC Remote visit and consultation software PATIENT
Slide 26: POHEMA
POHEMA Micro-Services Architecture
Slide 27: Vein-to-Vein Process
Blood Donor Centers Hospitals «VEIN-TO-VEIN» PROCESS
Slide 28: Global Competitors
ranks 5th on the global market of Blood transfusion sw GLOBAL France COMPETITORS USA USA USA Italy USA USA Australia USA Germany USA China China China USA Source: QY Research
Slide 29: IR Contact details
IR Contact details Via Ragazzi del '99, 13 - 38123 Trento T +39 0461 381515 investor.relations@gpi.it Fabrizio Redavid Lorenzo Giollo C. +39 335 1035499 C. +39 340 8223333 fabrizio.redavid@gpi.it lorenzo.giollo@gpi.it - Maggio 2018
Slide 30: Disclaimer
Disclaimer The material in this presentation was prepared by GPI S.p.A. ("GPI” or the “Company”) without any paragraph 2, letters a) to d) of the Order; and (C) other persons to whom this presentation can be form of independent verification; it is general, basic information about the current busines